C3271470||Chondrocyte proliferation
C0007620||viability
C0007589||differentiation
C1533734||administration
C0025810||methylphenidate
C0087111||treatment
C1263846||attention-deficit/hyperactivity disorder
C1320172||Methylphenidate (MPH) derivative
C1254351||drugs
C0304403||psychostimulants
C1263846||attention-deficit hyperactivity disorder
C0243095||anti-proliferative effects
C0025810||Methylphenidate
C0007301||cartilage tissue
C0023866||literature
C2603343||study
C0332149||possible
C0025810||Methylphenidate
C3271470||proliferation
C0007620||viability
C0007589||differentiation
C0086418||human
C0225369||chondrocytes
C0225369||chondrocyte
C4082130||prepared
C2937247||osteochondral
C0040300||tissue
C0086511||total knee prosthesis operation
C0525069||Stock solution
C0025810||Methylphenidate
C4082130||prepared
C0525069||solutions
C4283957||wells
C0225369||cultured chondrocyte
C0180454||well plates
C0225369||chondrocyte
C0243095||no solution
C0332149||possible
C0205160||negative
C1254351||drug
C0225369||chondrocytes
C0025810||Methylphenidate
C0007620||viability
C0596290||proliferation
C0080188||stage-specific embryonic antigen-1
C1171362||protein expression
C0871685||clinicians
C1254351||drug
C3271470||chondrocyte cell proliferation
C0007589||chondrogenic differentiation